Related Experiment Videos
Autologous bone marrow transplantation for multiple myeloma
1Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock.
Hematology/Oncology Clinics of North America
|April 1, 1992
Summary
Intensive chemotherapy can significantly reduce multiple myeloma tumors, leading to complete remission. Stem cell support and growth factors now lower infection risks and severe side effects.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Multiple myeloma treatment traditionally involves chemotherapy with significant toxicities.
- Achieving complete remission is a key goal in managing multiple myeloma.
Purpose of the Study:
- To evaluate the efficacy of intensive cytotoxic chemotherapy in achieving tumor cytoreduction in multiple myeloma.
- To assess the impact of autologous stem cell support and growth factors on treatment-related toxicities.
Main Methods:
- Utilized intensive cytotoxic chemotherapy regimens for multiple myeloma patients.
- Employed autologous marrow and blood stem cells for transplantation.
- Administered growth factors to support hematological recovery.
Main Results:
- Intensive chemotherapy demonstrated significant tumor cytoreduction.
- Achieved true complete remissions in a notable proportion of patients.
- Reduced risks of infection and severe extramedullary toxicities through stem cell support and growth factors.
Conclusions:
- Intensive cytotoxic chemotherapy is a potent strategy for managing multiple myeloma.
- Autologous stem cell transplantation and growth factors enhance treatment safety and tolerability.